Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
48°
Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Arrowhead Pharma
(NQ:
ARWR
)
23.29
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
23.29
Bid (Size)
22.56 (1)
Ask (Size)
23.79 (1)
Prev. Close
23.29
Today's Range
23.29 - 23.29
52wk Range
20.67 - 42.48
Shares Outstanding
105,736,200
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
April 24, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
April 24, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Performance
YTD
-24.90%
-24.90%
1 Month
-16.49%
-16.49%
3 Month
-29.02%
-29.02%
6 Month
-2.88%
-2.88%
1 Year
-30.64%
-30.64%
More News
Read More
Turnstone Biologics Appoints William Waddill to its Board of Directors
April 16, 2024
From
Turnstone Biologics Corp.
Via
GlobeNewswire
Cracking The Code: Understanding Analyst Reviews For Arrowhead Pharma
February 07, 2024
Via
Benzinga
Recap: Arrowhead Pharma Q1 Earnings
February 06, 2024
Via
Benzinga
Earnings Scheduled For February 6, 2024
February 06, 2024
Via
Benzinga
Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
April 07, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
The 7 Most Undervalued Russell 2000 Stocks to Buy in April 2024
April 05, 2024
Via
InvestorPlace
NetApp, Zoom Video And 2 Other Stocks Insiders Are Selling
April 04, 2024
Via
Benzinga
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
April 01, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
March 25, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
March 13, 2024
Via
InvestorPlace
The 3 Most Undervalued Russell 2000 Stocks to Buy in March 2024
March 11, 2024
Via
InvestorPlace
EQT, Genie Energy And Other Big Stocks Moving Lower On Monday
March 11, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
March 08, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
March 04, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
March 01, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
7 Oversold Russell 2000 Stocks to Add to Your February Buy List
February 25, 2024
Via
InvestorPlace
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
February 23, 2024
Via
Investor's Business Daily
7 Biotech Stocks Fighting America’s Deadliest Diseases
February 08, 2024
Via
InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
February 06, 2024
Via
Benzinga
Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results
February 06, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results
January 22, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million
January 05, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Via
Investor's Business Daily
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.